A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Trial details
- Registry ID
- NCT07142811
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as VIR-2218
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 | VIR | Phase 2 | Active not recruiting | 2029-03Estimated |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 | VIR | Phase 3 | Active not recruiting | 2026-12Estimated |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338 | VIR | Phase 3 | Active not recruiting | 2026-09-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |